Title: Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding RNAs
Patent Number: 8,133,876
Filed: Dec. 30, 2008
Lead Inventor: Frank Bennett, Regulus Therapeutics
The invention, the patent's abstract states, comprises “compounds, compositions, and methods ... for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs, as well as downstream targets of these RNAs, and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.”
Title: Lipids and Compositions for the Delivery of Therapeutics
Application Number: 20120058144
Filed: Nov. 10, 2009
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
The invention, the patent application's abstract states, “provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.”
Title: Lipid-Encapsulated Interfering RNA
Application Number: 20120058188
Filed: June 24, 2011
Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics (Tekmira Pharmaceuticals)
The invention provides “compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell,” the patent application's abstract states.
Title: Adenoviral VA1 Pol III Expression System for RNAi Expression
Application Number: 20120058522
Filed: Aug. 25, 2011
Lead Inventor: John Rossi, City of Hope
The invention, the patent application's abstract states, comprises “an adenoviral VA1 Pol III expression system for RNAi expression.”
Title: RNAi-Expression Constructs
Application Number: 20120058555
Filed: Nov. 10, 2011
Lead Inventor: Petrus Roelvink, Benitec Biopharma
The invention, the patent application's abstract states, “provides compositions and methods suitable for expressing 1-x RNAi agents against a gene or genes in cells, tissues, or organs of interest in vitro and in vivo so as to treat diseases or disorders.”
Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using miR-10a
Application Number: 20120058915
Filed: Nov. 15, 2011
Lead Inventor: Carlo Croce, Ohio State University
The invention, the patent application's abstract states, “provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”
Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using miR-203
Application Number: 20120058914
Filed: Nov. 15, 2011
Lead Inventor: Carlo Croce, Ohio State University
The invention, the patent application's abstract states, “provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”
Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using miR-16b
Application Number: 20120058913
Filed: Nov. 14, 2011
Lead Inventor: Carlo Croce, Ohio State University
The invention, the patent application's abstract states, “provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”
Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using let-7g
Application Number: 20120058912
Filed: Nov. 14, 2011
Lead Inventor: Carlo Croce, Ohio State University
The invention, the patent application's abstract states, “provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”
Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using miR-181b
Application Number: 20120058911
Filed: Nov. 14, 2011
Lead Inventor: Carlo Croce, Ohio State University
The invention, the patent application's abstract states, “provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”
Title: Method of Diagnosing Acute Lymphomic Leukemia Using miR-125b
Application Number: 20120058910
Filed: Oct. 17, 2011
Inventor: Carlo Croce, Ohio State University
The patent application, its abstract states, claims “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins.”
Title: Inhibition of MAP4K4 Through RNAi
Application Number: 20120059046
Filed: Nov. 19, 2009
Lead Inventor: Tod Woolf, RXi Pharmaceuticals
The patent application, its abstract states, claims “RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities. … The blunt-ended constructs have a double-stranded region of 19 [to] 49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity.”
Title: Differentiation Therapy for Sarcomas
Application Number: 20120059159
Filed: May 25, 2009
Lead Inventor: Carola Ponzetto, University of Torino Medical School
The invention, the patent application's abstract states, comprises the “use of muscle-enriched/specific microRNAs for the treatment of sarcomas, as for example rhabdomyosarcomas, synovial sarcoma, alveolar soft part sarcoma, liposarcoma, and osteosarcoma, wherein the microRNAs are able to stop the development of neoplastic cells and to force the neoplastic cells to differentiate into terminally differentiated muscle cells.”